PRECISION BIOSCIENCES INC
About PRECISION BIOSCIENCES INC
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $34.3M
- Net income
- -$45.7M
- Total assets
- $154.4M
- Market cap
- $167.7M
- Operating margin
- -152.2%
- Net margin
- -133.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $34.3M
- Operating expenses
- $86.4M
- Operating income
- -$52.1M
- Income tax
- $0
- Net income
- -$45.7M
- EPS (basic)
- $-3.56
- EPS (diluted)
- $-3.56
Balance sheet
- Total assets
- $154.4M
- Current assets
- $118.7M
- Total liabilities
- $62.2M
- Current liabilities
- $8.9M
- Shareholders’ equity
- $92.2M
Cash flow
- Operating cash flow
- -$65.8M
- Investing cash flow
- -$634.0K
- Financing cash flow
- $95.2M
- Net cash flow
- $28.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $167.7M
- EPS (diluted)
- $-3.56
- Shares outstanding
- 26.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 28, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $45.7M in FY2025.
- Revenue declined 70% from FY2021 to FY2025.
- Trading 25% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review PRECISION BIOSCIENCES INC.
Write a review
News about PRECISION BIOSCIENCES INC
News & sentiment via Polygon.io
